{"classes":[{"categories":[{"measurements":[{"comment":"upper limit is not estimable","groupId":"OG000","lowerLimit":"16.76","upperLimit":"NA","value":"25.59"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"description":"Defined as the time from the start of combination therapy until death due to any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"INCAGN01876 in combination with pembrolizumab and epacadostat","id":"OG000","title":"INCAGN01876 + Pembrolizumab + Epacadostat"}],"paramType":"MEDIAN","populationDescription":"The FAS includes all participants enrolled in the study who received at least 1 dose of INCAGN01876, pembrolizumab, or epacadostat.","reportingStatus":"POSTED","timeFrame":"At 1 year and 2 years.","title":"Phase 1 & Phase 2: Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}